The U.S. Department of Veterans Affairs (VA) has announced funding for a study on Methylenedioxymethamphetamine-assisted (MDMA-assisted) therapy aimed at treating post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) among veterans. This marks the first VA-funded research into psychedelic-assisted therapy since the 1960s.
Researchers from Brown University and Yale University, affiliated with the VA, will assess MDMA-assisted therapy as a potential treatment for veterans suffering from both PTSD and AUD. The study involves psychotherapy sessions enhanced by MDMA, a psychedelic compound thought to increase emotional openness, reduce fear, and promote introspection during therapy. Some participants will receive an active placebo consisting of a lower dose of MDMA.
The research is set to take place at Providence VA Medical Center in Rhode Island and West Haven VA Medical Center in Connecticut, with enrollment expected to begin in fiscal year 2025. The project has been awarded approximately $1.5 million over five years. As per standard procedure for all VA studies, treatments will occur in clinical settings under strict safety protocols while adhering to federal guidelines concerning controlled substances. Pharmaceutical-grade MDMA will be used, and participants' well-being will be closely monitored throughout the study.
This initiative is part of a broader effort by the VA and the Biden-Harris Administration to enhance veteran health through evidence-based treatments. In January, the administration announced plans to gather definitive scientific evidence regarding the efficacy and safety of psychedelic compounds like MDMA and psilocybin when combined with psychotherapy for treating conditions such as PTSD and depression among veterans.
“VA is on the cutting edge of clinical research for Veteran health, including in the investigation of psychedelics for mental health,” stated Under Secretary for Health Shereef Elnahal, M.D. “This study will give us better insight into the potential of MDMA-assisted therapy as a treatment for Veterans.”
Psychedelic drugs are known to alter consciousness or awareness and can be either organically or synthetically produced. The VA advises against self-medicating with psychedelics or any unprescribed substances due to risks such as serious self-injury or harm. Veterans are encouraged to consult healthcare providers before making any treatment decisions.
Veterans struggling with mental health or substance-use disorders can access resources provided by the VA. Information about participating in VA research is available.
